Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05390515 · ClinicalTrials.gov registry record · Phase 4
Psoriatic Immune Response to Tildrakizumab
A Phase 4 study, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT05390515 is a Phase 4 study that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 10 participants.
The verdict
NCT05390515, a Phase 4 study, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
Interventions
- DRUG Tildrakizumab Prefilled Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2028-09-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05390515
The ClinicalTrials.gov registry entry for NCT05390515 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tildrakizumab Prefilled Syringe is the first listed.
NCT05390515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05390515 about?
NCT05390515 is a clinical study titled "Psoriatic Immune Response to Tildrakizumab". This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.
What is the current status of trial NCT05390515?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2022-09-01. Estimated completion is 2028-09-01.
What interventions are being tested in trial NCT05390515?
The interventions under investigation include: Tildrakizumab Prefilled Syringe (DRUG).
Who is sponsoring clinical trial NCT05390515?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.